Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers

Detalles Bibliográficos
Autores principales: Ysebaert, L, Laprévotte, E, Klein, C, Quillet-Mary, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670946/
https://www.ncbi.nlm.nih.gov/pubmed/26565404
http://dx.doi.org/10.1038/bcj.2015.93
_version_ 1782404333666566144
author Ysebaert, L
Laprévotte, E
Klein, C
Quillet-Mary, A
author_facet Ysebaert, L
Laprévotte, E
Klein, C
Quillet-Mary, A
author_sort Ysebaert, L
collection PubMed
description
format Online
Article
Text
id pubmed-4670946
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46709462015-12-14 Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers Ysebaert, L Laprévotte, E Klein, C Quillet-Mary, A Blood Cancer J Letter to the Editor Nature Publishing Group 2015-11 2015-11-13 /pmc/articles/PMC4670946/ /pubmed/26565404 http://dx.doi.org/10.1038/bcj.2015.93 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Letter to the Editor
Ysebaert, L
Laprévotte, E
Klein, C
Quillet-Mary, A
Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
title Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
title_full Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
title_fullStr Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
title_full_unstemmed Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
title_short Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
title_sort obinutuzumab (ga101) is highly effective against chronic lymphocytic leukemia cells in ex vivo b-cell depletion irrespective of high-risk prognostic markers
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670946/
https://www.ncbi.nlm.nih.gov/pubmed/26565404
http://dx.doi.org/10.1038/bcj.2015.93
work_keys_str_mv AT ysebaertl obinutuzumabga101ishighlyeffectiveagainstchroniclymphocyticleukemiacellsinexvivobcelldepletionirrespectiveofhighriskprognosticmarkers
AT laprevottee obinutuzumabga101ishighlyeffectiveagainstchroniclymphocyticleukemiacellsinexvivobcelldepletionirrespectiveofhighriskprognosticmarkers
AT kleinc obinutuzumabga101ishighlyeffectiveagainstchroniclymphocyticleukemiacellsinexvivobcelldepletionirrespectiveofhighriskprognosticmarkers
AT quilletmarya obinutuzumabga101ishighlyeffectiveagainstchroniclymphocyticleukemiacellsinexvivobcelldepletionirrespectiveofhighriskprognosticmarkers

Ejemplares similares